|Articles|December 6, 2022
Further Discussion on Plasmids to Establish Release Specifications Using a Risk-Based Approach to Manage Supply
Author(s)Eurofins
A panel of experts from bio/pharmaceutical companies discuss plasmids to establish specifications using a risk-based approach to manage supply, including the response to cell & gene therapy industry feedback, future outlook and re-evaluating plasmid risks.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
CNPV Deep Dive: Perspectives on Accelerated FDA Review From the C-Suite to the Manufacturing Floor
2
De-risking Biologic Development: Engineering Flexibility from Early Development to Launch
3
Multi-Compendial Compliance for Pharmaceutical Excipients–Part 1: A Practical Application of Specification Equivalence
4
Momentum and Automation Driving Pharma Innovation and Digitalization Through 2026
5